LAVCA VC
  • News Feed
  • VC Data
  • Directories
  • Features
  • Tech Growth Coalition
  • LAVCA Gender Diversity
  • Engage
    • VC Council
    • VC Members
  • LAVCA
  • Member Login
  • Member Access

LAVCA VC

  • News Feed
  • VC Data
  • Directories
  • Features
  • Tech Growth Coalition
  • LAVCA Gender Diversity
  • Engage
    • VC Council
    • VC Members
  • LAVCA

Advent’s Biotoscana Agrees to Acquire United Medical to Expand Commercial Presence in Brazil

13 January 2014

(BusinessWire) Grupo Biotoscana, a pharmaceutical company based in Bogotá, Colombia, and majority owned by Advent International and Essex Woodlands, today announced that it has signed an agreement to acquire United Medical, a group of pharmaceutical companies based in São Paulo, Brazil, to create a leading specialty pharmaceutical company with commercialization capabilities throughout South America. The acquisition will broaden Biotoscana’s portfolio of innovative licensed products as well as its geographic sales and marketing capabilities by expanding into the $28 billion Brazilian pharmaceutical market.

“We believe this combination will further strengthen our commitment to patients in Latin America and look forward to working with the Biotoscana management team to advance this mission.”

United Medical is focused on the critical care market in Brazil and is partner to several large biotechnology and pharmaceutical companies, including Gilead Sciences Inc. The combined company will focus on critical and specialty care, oncology, hematology, hospital-based products, orphan drugs, pain and gastroenterology, and will have a deep commercial presence in Brazil, Colombia, Argentina, Chile, Peru and Ecuador. Pro forma for the acquisition, the enlarged group will have a sales force of over 225 representatives and revenue of approximately US$200 million.

“The acquisition of United Medical solidifies our position as a pan-Latin American pharmaceutical company focused on commercializing innovative products that serve significant unmet needs,” said Juan Camilo Palacio, Chief Executive Officer of Biotoscana. “United Medical has a strong commercial presence in the Brazilian specialty pharmaceutical market and a complementary product portfolio, which will strengthen our position in the region.”

“We are delighted to be joining forces with Biotoscana in Latin America,” commented Roberto Guttman, Chief Executive Officer of United Medical. “We believe this combination will further strengthen our commitment to patients in Latin America and look forward to working with the Biotoscana management team to advance this mission.”

The Latin American pharmaceutical market is one of the fastest growing markets of its kind in the world. With a combined population of more than 600 million, a rapidly growing middle class and universal health care coverage in most countries, the 2013 pharmaceutical market of nearly US$70 billion is expected to experience double-digit growth over the next decade. Biotoscana seeks to pursue this significant opportunity by broadening its existing commercial portfolio through partnerships with leading pharmaceutical and biotechnology companies for differentiated value-add products in its core therapeutic areas.

The transaction, which is subject to customary closing conditions, including Brazilian antitrust regulatory approval, is expected to close in the first quarter of 2014. Financial terms of the transaction were not disclosed.

Biotoscana was advised on the transaction by Lobo de Rizzo Advogados and Bonn Steichen & Partners. United Medical was advised by Apeiron Partners LLC (Boston, MA) and Schivartche Advogados (São Paulo, Brazil).

Advent’s Biotoscana Agrees to Acquire United Medical to Expand Commercial Presence in Brazil was last modified: January 17th, 2014 by Editor
AcquisitionsAdvent InternationalColombiaEssex WoodlandsPharmaceuticalSouth AmericaUnited Medical
0
Facebook Twitter Google +

Tech Growth Membership

The 2023 LAVCA Startup Founders Survey is made possible thanks to the support of LAVCA’s Tech Growth Membership, a group of leading tech companies and investors advancing the tech ecosystem in Latin America including AWS, Mercado Libre, Microsoft, Qualcomm Ventures, SVB, Riverwood Capital, Google and Movile.

VC Partner Events

    Tweets

    Missing consumer key - please check your settings in admin > Settings > Twitter Feed Auth

    Submit VC News

    Have private equity or venture capital related news that you would like to share? Submit your press releases and news to [email protected].

    VC Industry News

    • Valor Capital Group and NFX Co-Lead USD9.3m Series A for Brazil’s Praso

      30 August 2023
    • EQT Growth Leads USD85m Series F for Brazil’s Gympass at USD2.2b Valuation

      23 August 2023
    • Tiger Global Leads USD61m Series B for Brazil’s Nomad 

      22 August 2023
    • NASZCA and IDB Invest Lead USD15.5m Series A for Mexico’s Wonder Brands

      17 August 2023
    • Victory Park Capital Provides USD100m Credit Facility for Mexico’s Klar

      15 August 2023
    • General Catalyst Lead USD45m Series B for Brazil’s Tractian

      7 August 2023
    • General Catalyst Leads USD45m Round for Brazil’s Tractian

      7 August 2023
    • ADQ Provides USD100m In Convertible Debt to Brazil’s Loft

      2 August 2023
    • Danish SDG Investment Fund Leads USD31.5m Series C for Mexico’s Bright  

      27 July 2023
    • Colombia’s Foodology Raises USD17m from Andreessen Horowitz, 30N Ventures and Chimera

      19 July 2023

    About LAVCA

     

    LAVCA is the Association for Private Capital Investment in Latin America, a not-for-profit membership organization dedicated to supporting the growth of private capital in Latin America and the Caribbean through research, education, networking and advocacy.

    LAVCA Office

        New York City:
        589 8th Ave, 18th Floor
        New York, NY 10018

    Explore LAVCA.org

    • About LAVCA
    • Board, Team, & Advisors
    • Media
    • Contact Us
    • Membership Benefits
    • Members Only Access
    • Education and Programs
    • Research
    • Policy
    • LAVCA VC
    • Contact Us

    @2020 - LAVCA. All Rights Reserved.


    Back To Top